3-chloro-4-(5-chloro-2-hydroxybenzamido)benzoic acid | 1428328-98-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-chloro-4-(5-chloro-2-hydroxybenzamido)benzoic acid
• 英文别名: 3-Chloro-4-[(5-chloro-2-hydroxybenzoyl)amino]benzoic acid
• CAS: 1428328-98-6
• 化学式: C₁₄H₉Cl₂NO₄
• 分子量: 326.136
• InChiKey: GFOJOCINFDWDMH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  86.6
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-chloro-4-(5-chloro-2-hydroxybenzamido)benzoic acid 、 乙酸酐 在 硫酸 作用下， 反应 24.0h， 以46.3%的产率得到4-{[2-(acetyloxy)-5-chlorobenzene]amido}-3-chlorobenzoic acid
  参考文献：
  名称：

  [EN] COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS AND SYNTHESIS OF THE SAME
  [FR] COMPOSÉS UTILES DANS LE TRAITEMENT DE TROUBLES MÉTABOLIQUES ET LEUR SYNTHÈSE

  摘要：

  本发明提供了式(I)化合物：其中变量X、Y、Z和R1如本文所述。本文所述的一些化合物是谷氨酸脱氢酶激活剂。本发明还涉及包含这些化合物的药物组合物、这些化合物和组合物在治疗代谢紊乱中的用途以及这些化合物的合成。

  公开号：

  WO2014165816A1
• 作为产物：
  描述：

  methyl 3-chloro-4-[(5-chloro-2-methoxybenzene)amido]benzoate 在 三溴化硼 、 sodium hydroxide 作用下， 以 二氯甲烷 、 乙醇 为溶剂， 反应 10.0h， 生成 3-chloro-4-(5-chloro-2-hydroxybenzamido)benzoic acid
  参考文献：
  名称：

  新型氯硝柳胺衍生佐剂可提高多粘菌素 B 对 MDR 铜绿假单胞菌 DK2 的功效

  摘要：

  铜绿假单胞菌 (P. aeruginosa) DK2 是一种多重耐药 (MDR) 革兰氏阴性细菌病原体，被观察到对“最后手段”抗生素多粘菌素 B (PB) 有严重耐药性。与佐剂的联合治疗已成为重新激活 MDR 细菌耐药性抗生素的有效策略。在这里，我们筛选了一个获批药物库，发现一种驱虫药物氯硝柳胺 (NIC) 可以增强 PB 对 MDR铜绿假单胞菌DK2 的功效。接下来，设计、合成了一系列新型 NIC 衍生佐剂，并评估了与 PB 的协同活性。其中，15与 PB 的组合显示出对铜绿假单胞菌DK2的优异消除体外和体内与单次给药相比。此外，这种组合减缓了 DK2 的 PB 抗性进展，同时降低了潜在毒性。总体而言，这项研究提供了开发抗生素佐剂以增强 PB 对抗 MDR铜绿假单胞菌感染的策略。

  DOI：

  10.1016/j.ejmech.2022.114318

文献信息

• COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS AND SYNTHESIS OF THE SAME
  申请人：NORTH CAROLINA CENTRAL UNIVERSITY

  公开号：US20160046560A1

  公开（公告）日：2016-02-18

  The present invention provides compounds of Formula (I): wherein variables X, Y, Z and R1 are as described herein. Some of the compounds described herein are glutamate dehydrogenase activators. The invention is also directed to pharmaceutical compositions comprising these compounds, uses of these compounds and compositions in the treatment of metabolic disorders as well as synthesis of the compounds.

  本发明提供了一些式子为(I)的化合物：其中变量X、Y、Z和R1如本文所述。其中一些化合物是谷氨酸脱氢酶激活剂。本发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在治疗代谢性疾病方面的用途以及化合物的合成。
• Exploring Structure–Activity Relationships of Niclosamide-Based Colistin Potentiators in Colistin-Resistant Gram-Negative Bacteria
  作者：Liam Berry、Quinn Neale、Rajat Arora、Danyel Ramirez、Marc Brizuela、Ronald Domalaon、Gilbert Arthur、Frank Schweizer

  DOI：10.3390/antibiotics13010043

  日期：——

  Colistin is primarily used as a last resort antibiotic against highly resistant Gram-negative bacteria (GNB). Rising rates of colistin resistance, however, may limit future use of this agent. The anthelmintic drug niclosamide has been shown to enhance colistin activity in combination therapy, but a detailed structure–activity relationship (SAR) for niclosamide against GNB has yet to be studied. A series

  粘菌素主要用作针对高度耐药革兰氏阴性菌 （GNB） 的最后抗生素。然而，粘菌素耐药率的上升可能会限制该药物的未来使用。驱虫药氯硝柳胺已被证明在联合治疗中可增强粘菌素活性，但氯硝柳胺对 GNB 的详细构效关系 （SAR） 尚未研究。合成了一系列氯硝柳胺类似物进行 SAR，从而发现了一种先导化合物，该化合物显示出与氯硝柳胺相当的粘菌素增强活性，但细胞毒性降低。总体而言，这项工作为未来开发新型氯硝柳胺衍生物的合成策略提供了重要见解，并表明在维持粘菌素增强的同时可以降低对哺乳动物细胞的毒性。
• Compounds useful for the treatment of metabolic disorders and synthesis of the same
  申请人：NORTH CAROLINA CENTRAL UNIVERSITY

  公开号：US10005720B2

  公开（公告）日：2018-06-26

  The present invention provides compounds of Formula (I): wherein variables X, Y, Z and R1 are as described herein. Some of the compounds described herein are glutamate dehydrogenase activators. The invention is also directed to pharmaceutical compositions comprising these compounds, uses of these compounds and compositions in the treatment of metabolic disorders as well as synthesis of the compounds.

  本发明提供了式 (I) 的化合物：其中变量 X、Y、Z 和 R1 如本文所述。本文所述的一些化合物是谷氨酸脱氢酶激活剂。本发明还涉及包含这些化合物的药物组合物、这些化合物和组合物在治疗代谢紊乱中的用途以及化合物的合成。
• Small molecule modulators of Wnt/β-catenin signaling
  作者：Robert A. Mook、Minyong Chen、Jiuyi Lu、Larry S. Barak、H. Kim Lyerly、Wei Chen

  DOI：10.1016/j.bmcl.2013.01.101

  日期：2013.4

  The Wnt signal transduction pathway is dysregulated in many highly prevalent diseases, including cancer. Unfortunately, drug discovery efforts have been hampered by the paucity of targets and drug-like lead molecules amenable to drug discovery. Recently, we reported the FDA-approved anthelmintic drug Niclosamide inhibits Wnt/beta-catenin signaling by a unique mechanism, though the target responsible remains unknown. We interrogated the mechanism and structure-activity relationships to understand drivers of potency and to assist target identification efforts. We found inhibition of Wnt signaling by Niclosamide appears unique among the structurally-related anthelmintic agents tested and found the potency and functional response was dependent on small changes in the chemical structure of Niclosamide. Overall, these findings support efforts to identify the target of Niclosamide inhibition of Wnt/beta-catenin signaling And the discovery of potent and selective modulators to treat human disease. (C) 2013 Elsevier Ltd. All rights reserved.
• Compounds Useful for the Treatment of Metabolic Disorders and Synthesis of the Same
  申请人：North Carolina Central University

  公开号：US20180370905A1

  公开（公告）日：2018-12-27

  The present invention provides compounds of Formula (I): wherein variables X, Y, Z and R1 are as described herein. Some of the compounds described herein are glutamate dehydrogenase activators. The invention is also directed to pharmaceutical compositions comprising these compounds, uses of these compounds and compositions in the treatment of metabolic disorders as well as synthesis of the compounds.